Litigation Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)
✉ Email this page to a colleague
Biogen Inc. v. Sandoz Inc. (D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-09-09 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory B. Williams |
| Jury Demand | None | Referred To | |
| Parties | SANDOZ INC.; SANDOZ INTERNATIONAL GMBH | ||
| Patents | 10,119,976; 10,233,245; 6,509,376; 6,602,503; 7,320,999; 7,619,001; 7,803,840; 8,124,350; 8,399,514; 8,871,449; 9,493,567; 9,709,575 | ||
| Attorneys | Matthew A. Chivvis; Theresa Tan | ||
| Firms | Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen Inc. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-09-19 | 10 | Redacted Document | the ’845 patent is attached as Exhibit 3. U.S. Patent No. U.S. 10,119,976 118… 118. U.S. Patent No. 10,119,976 (“the ’976 patent”), entitled “Method of Assessing Risk of PML,”…and Declaration of Infringement of U.S. Patent No. 10,119,976) 217. Biogen re-alleges and…Page 2 of 107 PageID #: 1325 9,790,533; U.S. 10,119,976; U.S. 10,233,245; U.S. 10,308,706; U.S. 10,444,234…covered by US Patent claims and corresponding patent claims outside the US. The foregoing patent claims are | External link to document |
| 2023-02-23 | 136 | Redacted Document | 10,119,976, and U.S. Patent No. 11,280,794 for purposes of discovery for the preliminary injunction… the methods described in U.S. Patent Nos. 10,119,976 and 11,280,794, including whether Biogen… whether Biogen has marked that U.S. Patent Nos. 10,119,976 and 11,280,794 cover methods used by …including United States Patent Nos. 9,096,879; 10,844,416; 9,316,641; 10,119,976; and 11,280,794. …practice of the asserted claims of U.S. Patent Nos. 10,119,976 and 11,280,794 and how often and in | External link to document |
| 2022-12-08 | 56 | Redacted Document | the ’845 patent is attached as Exhibit 3. U.S. Patent No. U.S. 10,119,976 110… 110. U.S. Patent No. 10,119,976 (“the ’976 patent”), entitled “Method of Assessing Risk of PML,”… (Declaration of Infringement of U.S. Patent No. 10,119,976) 191. Biogen re-alleges and…,567; U.S. 10,233,245; U.S. 11,292,845; U.S. 10,119,976; U.S. 10,677,803; U.S. 11,280,794; U.S. 9,316,641…covered by US Patent claims and corresponding patent claims outside the US. The foregoing patent claims are | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
